Voyager Therapeutics(VYGR)

LEXINGTON, MABiotechnology1 H-1B visas (FY2023)

Focus: Voyager Therapeutics is a public biotechnology company specializing in AAV capsid gene therapy, headquartered in Lexington, MA. The company is focused on developing novel gene therapies for neurodegenerative diseases including Parkinson's, Huntington's, and Alzheimer's disease.

Gene Therapy

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Voyager Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Voyager Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$250M

Key Products

VP4896

Alzheimer's Disease

Growth

Only Phase 3 program in pipeline; represents primary near-term regulatory catalyst for company.

Pipeline & Clinical Trials

Help build intelligence for Voyager Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

FY 2025 revenue surged to $250M from $41M in FY 2024, signaling successful commercialization and financial inflection
Pioneering AAV gene therapy platform with specialized expertise in capsid engineering—a high-barrier-to-entry technology
Diverse pipeline across high-unmet-need CNS indications (Parkinson's, Huntington's, Alzheimer's) with Phase 3 catalyst potential

Watch Out For

Only 1 active job opening and minimal H1B sponsorship (1 approval in 2023) suggest limited hiring momentum and visa support
Early-stage pipeline dominated by Phase 1 programs (5 of 10 trials); Phase 3 program (VP4896 in Alzheimer's) is sole near-term approval driver

Generated by Claude from Voyager Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Clinical Trials (1)

NCT05490225Access Cannulation Trial II

N/A

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

Parkinson's Disease

N/A

Clinical Trials (1)

NCT03733496Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

N/A

Intraparenchymal rAAV1 -

Huntington Disease

PHASE_1

Clinical Trials (1)

NCT04885114Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease

Phase 1

VY-AADC01

Idiopathic Parkinson's Disease

PHASE_1

Clinical Trials (1)

NCT03065192Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Phase 1

VY-AADC02

Parkinson's Disease

PHASE_1

Clinical Trials (1)

NCT03562494VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

Phase 1

VY-AADC01

Parkinson's Disease

PHASE_1

Clinical Trials (1)

NCT01973543Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

Phase 1

VY7523

Alzheimer's Disease (AD)

PHASE_1_2

Clinical Trials (1)

NCT06874621VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

Phase 1/2

Leuprolide acetate

Alzheimer Disease

PHASE_2

Clinical Trials (1)

NCT00076440Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study

Phase 2

Leuprolide acetate

Alzheimer Disease

PHASE_2

Clinical Trials (1)

NCT00063310ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

Phase 2

VP4896

Alzheimer's Disease

PHASE_3

Clinical Trials (1)

NCT00231946ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Neurology, Nephrology

H-1B (2023): 1 approval

Publications: 25 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Neurology

9 pipeline

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$250M511%

R&D Spend

$92M(37%)52%

Net Income

$132M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier.

Molecular therapy : the journal of the American Society of Gene Therapy

2025

PMID:40340250

Lessons Learned from Monitoring Adeno-Associated Virus-9 Neutralizing Antibody (AAV9-NAb) Seroconversion in a Cohort of Cynomolgus Macaques (Macaca fascicularis).

Journal of the American Association for Laboratory Animal Science : JAALAS

2025

PMID:40783180

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Voyager Therapeutics(VYGR)

About Voyager Therapeutics

Why Work Here

Key Products

Pipeline & Clinical Trials

Watch Out For

Recent News · Voyager Therapeutics(1)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)